Drugs put FTSE in a spin

clock

The FTSE 100 Index fell 33.70 points, or 0.54%, to 6,180 points today after a gloomy performance from drug companies.

AstraZeneca tumbled 8.16% to £28.80 on news it has stopped the development of its experimental stroke drug NXY-059, as it failed to reduce significant disability in patients. GlaxoSmithKline slipped 3.97% to £14.51 despite raising earnings guidance for the year to mid-teens EPS growth from 12% previously, hiking its dividend and increasing its share buyback programme. British American Tobacco also fell 1.55% to £14.59, despite lifting nine month earnings by 13% to 75p, adding it is on track for a good year. Life insurer Aviva dropped 1.89% to £7.77 after it reported it had boosted nin...

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes

Join

 

Already a Professional Adviser member?

Login

More on Investment

Advisers expecting more of asset managers since Consumer Duty

Advisers expecting more of asset managers since Consumer Duty

‘We actually need to understand one another better’

Hope Coumbe
clock 28 March 2024 • 1 min read
Fears tech limitations could stall MPS on its upward trajectory

Fears tech limitations could stall MPS on its upward trajectory

‘There have been a few changes and challenges around growth in general’

Hope Coumbe
clock 27 March 2024 • 1 min read
Partner Insight: Beyond 60/40

Partner Insight: Beyond 60/40

Invesco
clock 27 March 2024 • 5 min read